GnRH for Luteal Support in IVF/ICSI/FET Cycles

University Reproductive Associates

Status and phase: Enrolling; Phase 4

Conditions: Infertility

Treatments: Drug: placebo; Drug: GnRH

Study type: Interventional

Funder types: Other

Identifiers

NCT02357654

PRO20140001128

Details and patient eligibility

About

During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .

Full description

see above

Enrollment: 350 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old.

Exclusion criteria

• day 3 transfers

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

350 participants in 2 patient groups, including a placebo group

GnRH agonist

Experimental group

Treatment:

Drug: GnRH

Placebo

Placebo Comparator group

Treatment:

Drug: placebo